New psoriasis pill shows promise in early trial

NCT ID NCT07129382

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 33 times

Summary

This study tests an experimental pill called CS32582 in adults with moderate to severe plaque psoriasis. The trial has two parts: a small dose-finding phase and a larger 12-week treatment phase involving about 200 people. Researchers will check if the drug safely reduces skin symptoms like redness and scaling.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Affiliated Hospital of Chengde Medical University

    NOT_YET_RECRUITING

    Chengde, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Beijing Friendship Hospital, Capital Medical University

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • First Hospital of Shanxi Medical University

    NOT_YET_RECRUITING

    Taiyuan, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking University People's Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shandong Provincial Hospital for Skin Diseases

    NOT_YET_RECRUITING

    Jinan, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shiyan People's Hospital

    NOT_YET_RECRUITING

    Shiyan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affliated Hospital of Wenzhou Medical University

    NOT_YET_RECRUITING

    Wenzhou, Zhengjiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Yiwu, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital )

    NOT_YET_RECRUITING

    Xi’an, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.